

What's on the Horizon for U.S. Drug Pricing Policy in 2019 and Beyond? /

On October 25, Avalere experts came together to discuss the latest policy developments related to drugs.

The webinar featured:

- [Matt Brow](#), President
- [Elizabeth Carpenter](#), Senior Vice President, Policy
- [Miryam Frieder](#), Vice President, Policy
- [Lance Grady](#), Vice President, Market Access & Reimbursement
- [Milena Sullivan](#), Director, Policy

The discussion focused on the following topics:

- Drug Pricing Blueprint Themes and Related Policy Activity
- Part B Reforms
- New Medicare Formulary Flexibilities
- What to Watch

Drug Pricing Blueprint Themes and Related Policy Activity

Earlier this year, the Trump administration released a [drug pricing blueprint and request for information](#). The Blueprint focused on the following areas: enhanced competition, management, and negotiation; transparency; and value-driven incentives. Since the blueprint's release, the administration has proposed or implemented several major drug pricing policies.

Part B Reforms

Avalere experts discussed the policies the administration could pursue to reform Part B, several of which later appeared in the administration's proposed International Pricing Index (IPI) Model, which was announced by President Trump immediately following the webinar. The IPI Model incorporates an international drug pricing index, negotiation of Part B drug prices by independent vendors, and a change to the Average Sales Price reimbursement methodology.



New Medicare Formulary Flexibilities

Recent administration activity has focused on increasing formulary flexibility in Medicare. Policy changes include allowing Medicare Advantage (MA) plans to implement [utilization management for Part B medicines](#) and permitting Part D plans to implement [indication-based formulary design](#).

What to Watch

Two proposed rules related to drug policy are expected in the coming weeks. The first is expected to address the Part C and D programs, while the second is expected to address rebate practices in the Part D program.

[Listen to the archived version of the webinar.](#)

For more on drug pricing policy, [connect with us](#).

###

Avalere Health, an Inovalon Company, is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, product solutions, and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit avalere.com, or follow us on Twitter [@avalerehealth](https://twitter.com/avalerehealth).

